| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
|
|---|
| Outline of Final Research Achievements |
In order to overcome intractable lung diseases, such as lung cancer and lung tuberculosis, it is highly efficient to deliver their therapeutic agents directly to the lesion sites by intratracheal insufflation. The nanocomposite particles (mean particle size: 7.8μm) consisting of PLGA (poly(lactic-co-glycolic) acid) nanoparticles (mean sizes: 190 nm) containing the antitubercular agent rifampicin were prepared. These particles were distributed homogeneously in the rat and mouse lungs by the intratracheal administration by the newly developed Venturi insufflator, showing efficient antitubercular effects. In addition, the antitumor agent cyclophosphamide (CPA) increased the population of the M1 lung macrophages located around the tumor cells and showed effective antitumor activity. The lipid A analog ONO-4007 enhanced these effects of CPA.
|
